|Bid||160.15 x 100|
|Ask||220.00 x 200|
|Day's Range||176.83 - 180.91|
|52 Week Range||161.09 - 209.22|
|PE Ratio (TTM)||181.72|
|Dividend & Yield||0.91 (0.51%)|
|1y Target Est||N/A|
BioCryst's oral hereditary angioedema drug candidate hit the mark in a second interim analysis.
The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.
Shares of Xenetic Biosciences sank on Monday after the Lexington biotech announced a significant setback in its collaboration with Shire plc on a hemophilia drug. Xenetic (XBIO), which has seven employees, announced disappointing results from a Phase 1/2 study of Shire’s SHP656 hemophilia A treatment using Xenetic’s PolyXen technology, which is designed to extend the half-life of drugs. While the technology did extend the half-life of SHP656, and there were no major side effects, Xenetic said the trial had missed its goal of enabling once-weekly dosing.